Samsung Biologics has extended its collaboration with LigaChem Biosciences for antibody-drug conjugate (ADC) services. The ...

Samsung Biologics, a global contract development and manufacturing organization (CDMO), has extended its collaboration with ...

Biocytogen (HKEX: 02315), a global biotech company dedicated to discovering and developing novel antibody therapeutics, announced the licensing of its ...

Oxford, UK and San Jose, California, 9 January 2024 - (OBT), a clinical stage oncology company with a pipeline of ...

We hoped industry layoffs would relent in 2024. That's not what happened. | As always, if you know of layoffs occurring at a ...

After inking a series of partnerships late last year, Lonza’s antibody-drug conjugate (ADC) specialist Synaffix is kicking ...

Araris will use its linker technology to generate multi-warhead ADCs for “undisclosed targets” provided by Chugai.

The FDA’s breakthrough therapy designation for GSK’227 underscores its potential to address the critical unmet needs of ...

"FDA awards GSK breakthrough status for relapsed osteosarcoma treatment" was originally created and published by ...

The poster is titled Phase 1 Dose-Escalation Study of Next-Generation Nectin-4 Targeting Antibody-Drug Conjugate CRB-701 (SYS6002) in US And UK Patients with Urothelial Cancer and other Solid Tutors ...

Cancer screening is key to saving patients' lives since an earlier stage diagnosis improves survival rates, decreases morbidity, and leads to less intensive treatments.

GSK5764227 (HS-20093) is a novel antibody-drug conjugate composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload.